Recommended by the National Comprehensive Cancer Network® (NCCN®) as the preferred first-line therapy for iMCD

SYLVANT® (siltuximab) is the only therapy approved by the US Food and Drug Administration (FDA) for the treatment of people with multicentric Castleman disease (MCD) who are negative for human immunodeficiency virus (HIV) and human herpesvirus‑8 (HHV‑8).

The NCCN recommends using siltuximab as the first-line treatment for idiopathic multicentric Castleman disease (iMCD). SYLVANT is backed by the largest and most robust clinical studies in iMCD to date.

SYLVANT

The only targeted therapy approved and recommended by experts
A nurse and two doctors are prepared to help diagnose and treat symptoms of iMCD.
– Yankee, iMCD patient testimonial Sylvant

My doctor said he could give me a drug that would target IL-6. Siltuximab does this.

– Yankee, iMCD patient

SYLVANT targets and neutralizes IL-6

Interleukin-6 (IL-6) levels can be elevated in patients with iMCD and may be a cause of some iMCD symptoms. SYLVANT works by binding directly to IL-6 to prevent it from interacting with its target receptor, which is found on immune cells. SYLVANT has been shown to resolve the commonly observed symptoms of iMCD by neutralizing the effects of IL-6.

Overactivation of immune cells

In iMCD, excess amounts of a protein called IL-6 lead to overactivation of immune cells

excess amounts of a protein
Abnormal-IL-6

Abnormal IL-6 signaling may cause a cytokine storm that can lead to fever, night sweats, and unexplained weight loss, which are symptoms of iMCD

icon
overactivation-of-immune-cells

SYLVANT was designed to target IL-6, preventing it from causing a cytokine storm and the symptoms associated with iMCD

icon IL-6
icon Cytokines
icon Immune cells
icon IL-6 receptor
icon Cytokine storm
icon SYLVANT
See More

SYLVANT® (siltuximab) for injection

APPROVED USE

SYLVANT® (siltuximab) is a prescription medicine used to treat people with multicentric Castleman’s disease (MCD) who do not have human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8) infection.

It is not known if SYLVANT is safe and effective in children.

SYLVANT® (siltuximab) for injection

APPROVED USE

SYLVANT® (siltuximab) is a prescription medicine used to treat people with multicentric Castleman’s disease (MCD) who do not have human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8) infection.

It is not known if SYLVANT is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Do not take SYLVANT if you have had a severe allergic reaction to siltuximab or any of the ingredients in SYLVANT. See the Patient Information for SYLVANT for a complete list of ingredients.

Tell your healthcare provider if you have an infection. You should not receive SYLVANT if you have a severe infection.

Tell your healthcare provider if you have had a recent vaccination or are scheduled to receive any vaccinations. You should not receive a live vaccine during your treatment with SYLVANT.

Tell your healthcare provider if you are pregnant or plan to become pregnant. It is not known if SYLVANT will harm your unborn baby. You should not become pregnant while receiving treatment with SYLVANT. Females who are able to become pregnant should use effective birth control during treatment with SYLVANT and for 3 months after stopping treatment.

Tell your healthcare provider if you are breastfeeding or plan to breastfeed. It is not known if SYLVANT passes into your breast milk. You and your healthcare provider should decide if you will take SYLVANT or breastfeed. You should not do both.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of SYLVANT include rash, itching, upper respiratory tract infection, swelling, weight gain, and increased blood level of uric acid.

These are not all the possible side effects of SYLVANT. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

For more information, please see the full Prescribing Information.